Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

0.18
USD
+0.00
(+2.11%)
-1.68EPS
10.03MMarket Cap
Feb 11Next Earn

Total Valuation

USD

As of June 30, 2026, Vistagen Therapeutics, Inc. carries a market capitalization of 10.03M, placing it among publicly traded companies globally. Its enterprise value stands at -20.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.03M
Enterprise Value-20.92M

Important Dates

Vistagen Therapeutics, Inc.'s next confirmed earnings release is scheduled for February 11, 2027.

Earnings Date2/11/2027

Share Statistics

As of June 30, 2026, Vistagen Therapeutics, Inc. has 44.38M shares outstanding.

Shares Outstanding44.38M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 3.63, and the price-to-book ratio stands at 0.41.

PS Ratio3.63
PB Ratio0.41
P/TBV Ratio0.41
P/FCF Ratio-0.15
P/OCF Ratio-0.15

Financial Position

As of June 30, 2026, Vistagen Therapeutics, Inc. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

Current Ratio3.07
Quick Ratio2.84
Debt / Equity3.20
Debt / EBITDA-0.01

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. posted a negative return on equity (ROE) of -166.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -129.22, reflecting losses generated across the asset base. The company generates approximately 51,061.22 in revenue per employee across its workforce of 49.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-166.46
Return on Assets (ROA)-129.22
Revenue Per Employee51,061.22
Employee Count49.00

Taxes

USD

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. recorded 7,000.00 in income tax expense. The company reported a pretax loss of -67.61M and -67.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax7,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Vistagen Therapeutics, Inc.'s stock has declined approximately 95.15% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.42.

52-Week Price Change-95.15%
50-Day Moving Average0.22
200-Day Moving Average0.42

Income Statement

USD

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. generated 2.50M in revenue and converted that into -67.62M in net income, yielding earnings per share of -1.68. EBITDA reached -68.90M, while operating income came in at -69.66M.

Revenue2.50M
Operating Income-69.66M
Pretax Income-67.61M
Net Income-67.62M
EBITDA-68.90M
EBIT-69.66M
Earnings Per Share (EPS)-1.68

Balance Sheet

USD

As of June 30, 2026, Vistagen Therapeutics, Inc. holds 31.73M in cash and equivalents against 783,000.00 in total debt, resulting in a net debt position of -16.99M. Total book value stands at 24.48M, with working capital of 23.12M providing operational flexibility.

Cash & Cash Equivalents31.73M
Total Debt783,000.00
Net Debt-16.99M
Equity (Book Value)24.48M
Book Value Per Share0.55
Working Capital23.12M

Cash Flow

USD

Vistagen Therapeutics, Inc. produced -62.30M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -86,000.00 in capital expenditures, free cash flow totaled -62.38M - equivalent to -1.55 per share.

Operating Cash Flow-62.30M
Capital Expenditures-86,000.00
Free Cash Flow-62.38M
FCF Per Share-1.55

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -2,784.33 and net profit margin of -2,702.64 provide insight into operational efficiency.

Operating Margin-2,784.33
Pretax Margin-2,702.36
Profit Margin-2,702.64
EBITDA Margin-2,753.92

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -687.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -303.04, meaning Vistagen Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-303.04
FCF Yield-687.57

Stock Splits

Vistagen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.

Last Split Date6/7/2023
Split Ratio30:1

Scores

As of June 30, 2026, Vistagen Therapeutics, Inc. has an Altman Z-Score of -24.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-24.26